Tags : P-III KATHERINE study


Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP

Shots: The P-III KATHERINE study involves assessing of Kadcyla vs Herceptin + taxane-based CT as an adjuvant treatment in people with HER2-positive early breast cancer (eBC) who didn’t achieve pathological complete response to neoadjuvant treatment The P-III KATHERINE study met 1EP endpoints i.e. iDFS the time period to invasive breast cancer recurrence or death. No […]Read More